• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Post-Approval Studies (PAS)

  • Print
  • Share
  • E-mail

The FDA has the authority to require sponsors to perform a post-approval study (or studies) at the time of approval of a premarket approval (PMA), humanitarian device exemption (HDE), or product development protocol (PDP) application. Post-approval studies can provide patients, health care professionals, the device industry, the FDA and other stakeholders information on the continued safety and effectiveness (or continued probable benefit, in the case of an HDE) of approved medical devices. This database allows you to search Post-Approval Study information by applicant or device information.

Learn more...


AEGEA Pivotal Clinical Study

Suggest Enhancement / Report Issue | export reports to excelExport to Excel
Study Status Progress Adequate
Application Number P160047 / PAS001
Study Name AEGEA Pivotal Clinical Study
General Study Protocol Parameters
Study Design Prospective Cohort Study
Data Source New Data Collection
Comparison Group Objective Performance Criterion
Analysis Type Descriptive
Study Population Adult: >21
Detailed Study Protocol Parameters
Study Design Description The AEGEA Pivotal Clinical Trial (Protocol SE-3000) is a prospective, single-arm, non-randomized, multicenter, open label clinical trial to evaluate the safety and effectiveness of the AEGEA Vapor System™ for the treatment of excessive menstrual bleeding. Subjects were enrolled at fourteen investigational sites in the United States, Mexico, Canada, and The Netherland.

The AEGEA Pivotal Clinical Trial was divided into two groups: Safety subjects (or Safety cohort) and Pivotal subjects (or Pivotal cohort). Sixty-six (66) Safety subjects and 155 Pivotal subjects were evaluated. The primary analysis population for safety and effectiveness for this study was the Intent-to-Treat (ITT) population for the Pivotal subjects. Safety results from the Safety subjects were considered as part of the evaluation of device safety.

Data from the Pivotal cohort are the basis of effectiveness outcome analyses to support this PMA. Data from the Safety cohort is not included in the effectiveness analysis, but it is considered as a part of safety evaluation.

Follow-up of Pivotal cohort occurred at 24 hours post-procedure, 2 weeks and 3, 6, and 12 months post-procedure prior to PMA submission. The applicant intends to continue follow-up in the post-market setting to collect long-term outcome in Pivotal cohort at two and three years.
Study Population Description The demographics of the study population (Pivotal subjects) are typical for an endometrial ablation study performed in the United States. Seventy-six (76) patients were 30-39 years old, and seventy-nine (79) patients were 40-50 years old. The mean age of subjects at baseline was 39.8. An evaluation of these data confirmed the data could be pooled across sites and countries.

Sample Size One hundred and thirty-seven (137) of 155 Pivotal subjects enrolled in the premarket study are available for postmarket follow-up.

Data Collection Need for surgical or medical intervention to treat abnormal bleeding

Subject self-report of pregnancy

Contraception status (data to be collected at 3 years only)

Menstrual status

Gynecologic adverse events

Quality of Life questionnaire

Patient satisfaction

Follow-up Visits and Length of Follow-up Three years
Interim or Final Data Summary
Interim Safety Information Safety – At 24 months, 19 subjects reported gynecologic adverse events and no subject reported pregnancy following ablation.

Effectiveness – The outcomes at 24-month follow-up are

• 128 subjects reported no need for surgical or medical intervention to treat abnormal bleeding.

• Regarding quality of life, the mean Menorrhagia Impact Questionnaire (MIQ) was 6.1 at 24 months, compared to 6.6 at 12 months and 14.7 before treatment.

• 118 subjects were satisfied or very satisfied with the procedure, and 122 subjects would recommend the procedure to a friend.

• In terms of menstrual status, the number of subjects reported amenorrhea, light, moderate, heavy and very heavy bleeding was 33, 67, 26, 5 and 2, respectively.

AEGEA Pivotal Clinical Study Schedule

Report Schedule
Date Due
FDA Receipt
Applicant's Reporting Status
one year report 06/14/2018 05/25/2018 On Time
final report 11/29/2018 11/29/2018 On Time

Contact Us

Julie Unger
Project Manager, Post-Approval Studies Program
Food and Drug Administration
10903 New Hampshire Ave
WO66-4206v Silver Spring, MD

Phone: (301) 796-6134
Fax: (301) 847-8140

Related Links